Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 226

Results For "EMA"

2809 News Found

Kilitch Drugs earmarks Rs. 100 crore as part of its expansion
News | March 06, 2022

Kilitch Drugs earmarks Rs. 100 crore as part of its expansion

The company plans to establish a state-of-the-art greenfield pharma facility with a total of 4-6 manufacturing units in different therapeutics categories to cater to domestic and export markets


Healthium collaborates with Abhinav Bindra to treat sports injuries
Healthcare | March 06, 2022

Healthium collaborates with Abhinav Bindra to treat sports injuries

According to an Injury Surveillance Report by NCA last year, 14.75 % of players sustained shoulder injuries, 13.11% of players sustained knee injuries and almost 74 % players suffer from career-threatening Anterior Cruciate Ligament (ACL) injuries in the 1st two years of return to sport


Aquestive Therapeutics and Haisco Pharmaceutical partner for riluzole in China.
Biotech | March 06, 2022

Aquestive Therapeutics and Haisco Pharmaceutical partner for riluzole in China.

Around 85% of ALS patients suffer from a progressive loss of bulbar functionality


Govt announces over Rs 100 crore investment for Ayush sector in Nagaland
Public Health | March 04, 2022

Govt announces over Rs 100 crore investment for Ayush sector in Nagaland

Ten new Ayush hospitals and one Ayurvedic college will be set up in Nagaland and Mizoram


We plan to expand into the US market this year: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals
interviews | March 03, 2022

We plan to expand into the US market this year: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward


Cipla gets approval from SEC to conduct Paxlovid trials
News | March 03, 2022

Cipla gets approval from SEC to conduct Paxlovid trials

Paxlovid consists of nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating, and ritonavir, which slows down nirmatrelvir’s breakdown to help it remain in the body for a longer period at higher concentrations


Brinton ties up with Scholl Wellness Company
News | March 03, 2022

Brinton ties up with Scholl Wellness Company

Brinton Pharmaceuticals enters exclusive sales and distribution rights of Scholl foot care products including Krack cream


Limited impact of short-term disruptions, growth momentum to continue in FY 23
News | March 03, 2022

Limited impact of short-term disruptions, growth momentum to continue in FY 23

Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities


IHub-Data and IIIT-Hyderabad offer course on drug discovery
News | March 03, 2022

IHub-Data and IIIT-Hyderabad offer course on drug discovery

12-week certificate course commences on March 10th 2022


Avenge Bio announces peer-reviewed publication on preclinical proof of concept for LOCOcyte platform technology
Biotech | March 03, 2022

Avenge Bio announces peer-reviewed publication on preclinical proof of concept for LOCOcyte platform technology

Ovarian cancer is one of the most difficult cancers to treat. It is typically not detected until later stages, and about 70 percent of patients will have recurrence after an initial treatment, which is often fatal